이정민 (한동대학교)님 | 한빛사연구자 > 한빛사

한동대학교

최종업데이트 2023.04.18.

Current Knowledge and Future Perspectives on Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Agent
- Int. J. Mol. Sci., 2020 Jan 22;21(3):727 | https://doi.org/10.3390/ijms21030727
- 2020-01
- 생명과학
- 상위피인용논문
Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice
- Nucleic Acids Res., Published: 12 November 2019 | https://doi.org/10.1093/nar/gkz1070
- 2019-11
- 의약학
- 한빛사논문
CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis
- Sci. Adv., 30 Oct 2019 : Vol. 5, no. 10, eaax1210 | DOI: 10.1126/sciadv.aax1210
- 2019-10
- 생명과학
- 한빛사논문
- 이정민(Harvard University)
  1
mRNA-mediated glycoengineering ameliorates deficient homing of human stem cell–derived hematopoietic progenitors
- J. Clin. Invest., Published May 8, 2017 | doi:10.1172/JCI92030
- 2017-05
- 생명과학
- 한빛사논문

연구자 ID

저자논문